Jens H. Vogel, Ph.D. was previously President and CEO of Boehringer Ingelheim Fremont Inc. Jens has more than 20 years of experience in all aspects of biopharmaceutical development and manufacturing, through senior leadership roles in process & technology development, GMP manufacturing and global project leadership in the US, Germany and the UK. Prior,

Jens served as Global Head of CMC Strategy & TechRA, covering CMC development & global regulatory strategy for the entire portfolio of innovative BI biologics, biosimilars and contract development & manufacturing projects. Before joining Boehringer Ingelheim, Vogel was a Bayer’s Global Biologics Development Leadership Team member. Jens contributed to the successful licensure and post-launch support of multiple commercial biologics and more than 60 INDs/IMPDs. He was voted among the 100 most influential people in drug development and manufacture (The Medicine Maker Power List 2015). He holds a PhD in Biochemical Engineering from the University of Braunschweig, Germany and completed executive education programs at Harvard Business School, University of Notre Dame, Mendoza College of Business and Caltech.